• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Dihydroisoquinolines Dihydroisoquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Dihydroisoquinolines

Recent Advances in the Study of 1-Phenyl-3,4-dihydro-isoquinoline (CAS: 52250-50-7) in Chemical Biology and Pharmaceutical Research

1-Phenyl-3,4-dihydro-isoquinoline (CAS: 52250-50-7) is a structurally unique compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential as a scaffold for drug development, particularly in the context of central nervous system (CNS) disorders and cancer therapeutics. This research brief synthesizes the latest findings on this compound, highlighting its pharmacological properties, synthetic pathways, and therapeutic applications.

One of the most notable advancements in the study of 1-Phenyl-3,4-dihydro-isoquinoline is its role as a precursor in the synthesis of bioactive molecules. Researchers have demonstrated its utility in constructing complex heterocyclic frameworks, which are often found in drugs targeting neurotransmitter receptors. For instance, a 2023 study published in the Journal of Medicinal Chemistry detailed the compound's ability to modulate dopamine and serotonin receptors, suggesting its potential in treating psychiatric disorders such as depression and schizophrenia.

In addition to its CNS applications, 1-Phenyl-3,4-dihydro-isoquinoline has shown promise in oncology. A recent preclinical study revealed that derivatives of this compound exhibit potent inhibitory effects on certain kinase enzymes involved in cancer cell proliferation. The study, conducted by a team at the National Cancer Institute, identified specific structural modifications that enhance the compound's selectivity and efficacy against tumor cells while minimizing off-target effects.

The synthetic accessibility of 1-Phenyl-3,4-dihydro-isoquinoline has also been a focal point of recent research. Innovative catalytic methods, such as asymmetric hydrogenation and photoredox catalysis, have been employed to produce enantiomerically pure forms of the compound. These advancements are critical for ensuring the reproducibility and scalability of its derivatives in drug development pipelines.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and safety profiles of 1-Phenyl-3,4-dihydro-isoquinoline-based therapeutics. Future research directions may include in vivo toxicity studies and the exploration of novel delivery systems to improve bioavailability. Collaborative efforts between academic institutions and pharmaceutical companies will be essential to translate these findings into clinically viable treatments.

In conclusion, 1-Phenyl-3,4-dihydro-isoquinoline (CAS: 52250-50-7) represents a versatile and pharmacologically relevant scaffold with broad applications in drug discovery. Continued investigation into its mechanisms of action and synthetic optimization will undoubtedly contribute to the development of next-generation therapeutics for complex diseases.

• 52250-51-8(3,4-Dihydro-1-phenylisoquinoline Hydrochloride)
• 87870-21-1(Isoquinoline, 3,4-dihydro-4-methyl-1-phenyl-)
• 59261-37-9(1,4-Dimethyl-3,4-dihydroisoquinoline)
• 61305-03-1(Isoquinoline, 3,4-dihydro-1-(4-methylphenyl)-)
• 77988-87-5(Isoquinoline,3,4-dihydro-1,4-diphenyl-)
• 26210-39-9(1-methyl-3,4-dihydroisoquinoline hydrochloride)
• 3230-65-7(3,4-Dihydroisoquinoline)
• 24464-44-6(Isoquinoline,3,4-dihydro-1-methyl-7-phenyl-)
• 2412-58-0(1-Methyl-3,4-dihydroisoquinoline)
• 88422-89-3(Isoquinoline, 3,4-dihydro-4,4-dimethyl-1-phenyl-)